Monday, 30 March 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 30 March 2026
News

New approval breaks 30yr drought

Posted 30 March 2026 PM

Just weeks after registering a self-injectable version of Vyvgart, argenx has now added chronic inflammatory demyelinating polyneuropathy (CIDP) to the neonatal Fc receptor blocker’s label.

The new indication specifically covers the treatment of adults with progressive or relapsing active CIDP after prior treatment with corticosteroids or immunoglobulins.

To see the whole article, please login

Popular

Tough times? Not for pharma's Rich Listers
Company unveils role 'streamlining'
Who's on the PBAC's July Agenda?
Australia riding 'escalator to failure'
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home